CNTB (Connect Biopharma Holdings) Cash-to-Debt : 526.45 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Connect Biopharma Holdings's cash to debt ratio for the quarter that ended in Dec. 2024 was 526.45.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Connect Biopharma Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Connect Biopharma Holdings's Cash-to-Debt or its related term are showing as below:

CNTB' s Cash-to-Debt Range Over the Past 10 Years
Min: 254.42 Med: 455.83 Max: 2141.73
Current: 526.45

During the past 6 years, Connect Biopharma Holdings's highest Cash to Debt Ratio was 2141.73. The lowest was 254.42. And the median was 455.83.

CNTB's Cash-to-Debt is ranked better than
83.4% of 1482 companies
in the Biotechnology industry
Industry Median: 7.44 vs CNTB: 526.45

Connect Biopharma Holdings Cash-to-Debt Historical Data

The historical data trend for Connect Biopharma Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Connect Biopharma Holdings Cash-to-Debt Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

1,126.65

2,141.73

353.64

254.42

526.45

Connect Biopharma Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial						353.64	221.38	254.42	339.00	526.45

Competitive Comparison of Connect Biopharma Holdings's Cash-to-Debt

For the Biotechnology subindustry, Connect Biopharma Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Connect Biopharma Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Connect Biopharma Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	93.708	/	(0.154	+	0.024)
	=	526.45

Connect Biopharma Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	93.708	/	(0.154	+	0.024)
	=	526.45

Connect Biopharma Holdings (NAS:CNTB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Connect Biopharma Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.